BLAINTRAVENOUSINJECTABLE1 Generic Approved
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE (tocilizumab-aazg) is an intravenous monoclonal antibody that antagonizes the interleukin-6 receptor, blocking a key inflammatory pathway. It is a biosimilar referencing the innovator tocilizumab, approved by the FDA on March 5, 2024. The drug is indicated for conditions driven by IL-6 mediated inflammation.
Growth
Early-stage biosimilar with moderate competitive pressure (30% intensity) suggests active market positioning and demand for field-based and medical affairs professionals.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TYENNE offers mid-career professionals the opportunity to build expertise in biosimilar commercialization, market access strategy, and payer negotiations in a high-growth therapeutic area. Roles emphasize contracting, provider education, and competitive positioning rather than traditional product development, with strong demand in field-based medical and commercial functions.
Brand Manager
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.